Why the study?
Procedural myocardial injury is the most common complication of elective PCI and is associated with future adverse cardiac events, but the effects of prolonged bivalirudin infusion on this injury were unclear.
Does prolonged infusion of bivalirudin for 4 h after ePCI reduce procedural myocardial injury in patients undergoing elective percutaneous coronary intervention?
Does prolonged infusion of bivalirudin for 4 h after ePCI reduce procedural myocardial injury in patients undergoing elective percutaneous coronary intervention?
Prolonged infusion of bivalirudin for 4 hours after elective PCI reduces the severity of procedural myocardial injury (absolute troponin change) without increasing the risk of bleeding.
Answers are grounded in this paper and cite their sources.
Prolonged bivalirudin infusion attenuates troponin rise after elective PCI without affecting PMI rates; extends RCT data on post-procedural anticoagulation duration.
Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (n = 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%], P = 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%], P = 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (P = 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%], P = 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding.ClinicalTrials.gov.Number: NCT04120961, 09/10/2019.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: